# Pulmologix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pulmologix

- Industry: Pharmaceuticals
- Headquarters: Stockholm, Sweden
- Website: www.pulmologix.com
- Total disclosed funding: $12M
- Latest round: Series B (Sep 16, 2014)
- Investors on record: 4

## About

Pulmologix specializes in innovative technological solutions for respiratory health, enabling healthcare providers to enhance patient outcomes and streamline clinical operations. Their offerings focus on addressing critical challenges in pulmonary care.Pulmologix, founded in 2014, is based in Stockholm, Sweden, and operates in the field of respiratory health technology. The company has undergone pivotal developments in its business strategy to ramp up its offerings. It has successfully completed 2 funding deals, with the latest being a Series B round on September 22, 2014, raising EUR 9.6 mn from investors including Heartcore Capital and Novo Holdings. This round brought the total amount raised by the company to EUR 9.6 mn.Pulmologix offers a range of advanced technological solutions tailored to improve operational efficiency in healthcare settings focused on respiratory issues. Their primary products facilitate optimized workflows, enhance patient engagement, and aim to reduce operational costs for healthcare providers. These solutions are utilized by various end users, including small to medium-sized enterprises (SMEs) and large healthcare organizations across North America, Europe, and parts of Asia, ensuring a broad reach to diverse client bases.The company's revenue model encompasses subscription services and direct sales of its core products, primarily through B2B transactions. Clients typically enter into contractual agreements to access flagship products, which are made available via tiered subscription plans that cater to different usage levels and feature access. Specific pricing details are not disclosed but play a crucial role in the company's revenue generation strategy.Following its recent Series B funding round in September 2014, Pulmologix plans to leverage the EUR 9.6 mn raised to accelerate the development of new products aimed at enhancing respiratory care solutions. The company is also targeting expansion into additional European markets and select regions in Asia by 2025, with a focus on establishing partnerships that facilitate entry into these markets. This strategic growth plan aims to bolster their market position and widen their customer base.

## Funding rounds

- Series B, Sep 16, 2014, $12M — Novo Holdings, Forbion, Heartcore Capital, HealthCap

## Investors

- Novo Holdings — Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- Heartcore Capital (https://capitalatlas.ai/funds/heartcore-capital) — Series B
- HealthCap — Series B